Baiaotai biological applied for raising 2 billion yuan from science and Technology Innovation Board

According to the prospectus, Biostar meets the fifth set of standards and conditions for listing on the science and technology innovation board< br / > the science and technology innovation board has set up five listing conditionsAccording to the development situation and recent situation under different market values, different thresholds can be selectedEven if it is not yet profitable, it can apply for listing< br / > 1The accumulated net profit for two years is more than 50 million yuan, or the net profit for the past year is more than 100 million yuan, and the estimated market value of the enterprise is more than 1 billion yuan< br / > 2The annual revenue is more than 200 million yuan, and more than 15% of the total revenue is used for R & D investmentThe estimated market value of the enterprise is more than 1.5 billion yuan3The annual revenue is more than 300 million yuan, and the net amount generated by the business activities in three years is more than 100 million yuan, and the market value is not less than 2 billion yuan< br / > 4The total annual revenue is more than 300 million yuan, and the estimated market value of the enterprise is more than 3 billion yuan< br / > 5The market value is expected to be no less than 4 billion yuanThe main business or products need to be approved by the relevant departments of the stateThere is a large market spaceAt present, phased results have been achievedPharmaceutical enterprises need to have at least one core product approved to carry out phase II clinical trials, and other enterprises that meet the positioning of scientific and technological innovation board need to have obvious technical advantages and meet the corresponding conditions< br / > up to now, there are 21 main products under research of biotherapex, including 1 product which has been submitted for listing, 4 products which are in phase III clinical research stage, 1 product which is in phase II clinical research stage and 4 products which are in phase I clinical research stage< br / > in the next three years, Biostar will accelerate the process of product industrialization and marketization around the development strategic planning, including completing the listing of bat1406 and bat2094 in China; completing the phase III clinical application of bat1706 in line with the requirements of Chinese and European and American regulations, And apply for listing in major global markets; complete phase III clinical research of bat8001; complete phase III clinical research of bat1806 in line with Chinese and European and American regulations; promote global or Chinese clinical trials of multiple innovative drugs and biological similar drugs< br / > original title: raise 2 billion yuan, and baiaotai biology applied for science and technology innovation board!